The Purinergic System as a Target for the Development of Treatments for Bipolar Disorder

Author(s)

Goncalves, Maria Carolina Bittencourt ; Andrejew, Roberta ; Gubert, Carolina

• Document type: Journal article
• Source: CNS DRUGS; v. 36, n. 8, p. 15-pg., 2022-07-13.

Abstract

The neurobiological and neurochemical mechanisms underlying the pathophysiology of bipolar disorder are complex and not yet fully understood. From circadian disruption to neuroinflammation, many pathways and signaling molecules are important contributors to bipolar disorder development, some specific to a disease subtype or a cycling episode. Pharmacological agents for bipolar disorder have shown only partial efficacy, including mood stabilizers and antipsychotics. The purinergic hypothesis for bipolar disorder emerges in this scenario as a promising target for further research and drug development, given its role in neurotransmission and neuroinflammation that results in behavioral and mood regulation. Here, we review the basic concepts of purinergic signaling in the central nervous system and its contribution to bipolar disorder pathophysiology. Allopurinol and novel P2X7 receptor antagonists are promising candidates for treating bipolar disorder. We further explore currently available pharmacotherapies and the emerging new purinergic targets for drug development in bipolar disorder. (AU)

• FAPESP's process: 19/24553-5 - The role of P2Y1 receptor in Parkinsons Disease
• Grantee: Roberta Andrejew Caetano
• Support Opportunities: Scholarships in Brazil - Doctorate